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• One in five participants (18%) in the 2018 EDRS reported recent (i.e., past six month) use
of capsules contents unknown, an increase from lowest use reported in 2015 (7%; 10% in
2013 when monitoring first began).
• An increase in use of capsules contents unknown was recorded in most jurisdictions from
2013 to 2018. In 2018, 36% of the Tasmanian sample reporting recent use of capsules
contents unknown, compared to 12% in the New South Wales and Queensland samples.
• In 2018, people who had used capsules contents unknown did so infrequently (median 2
days in past six months) and most (62%) reported using one capsule in a typical session.
• Without objective data on content, all drug consumption can essentially be considered use
of an unknown substance. Whilst there are indications that people may modify their
behaviour to reduce risk of harm (e.g., reduced quantity and frequency of capsules
compared to where sold as a particular drug such as ecstasy), this trend raises concern
regarding risk of harm.
• Future data collection will evaluate broader use of substances without communication of
likely contents when sold, and adverse health events associated with use.
• People who use illicit drugs rely on the people who supply these substances as a primary
source of information of the likely contents of the substance [1], particularly in the absence
of drug checking facilities which provide objective data on contents. This information
informs expectations of likely effects and implementation of harm reduction strategies (e.g.,
checking interactions with other drugs, dosing) by an individual to reduce risk of
experiencing harm [2-3].
• Anecdotal reports in various jurisdictions in 2011/12 suggested a growing trend of
purchasing ‘capsules contents unknown’ (i.e., where there is no exchange of information
regarding likely contents of the capsule).
• These reports occurred at a time when data from people who use ecstasy and other illicit
stimulants indicated that use of ecstasy capsules nationally was increasing (and use of
ecstasy pills beginning to decline) [4].
• Number of new psychoactive substances (NPS) identified also proliferated in this period,
and reports of consumption of NPS (including stimulant NPS such as mephedrone often
sold in capsules) was growing [4].
• Use of ‘capsules contents unknown’ thus has caused significant concern with respect to the
wide variety of substances that might be contained within, and elevated risk of harm.
• Data were obtained between 2013-2018 from the Ecstasy and Related Drugs
Reporting System (EDRS) interviews.
• Annual interviews are conducted in each capital city with a sentinel sample of people
who regularly use ecstasy and other stimulants recruited through social media and
word-of-mouth. Full details of the methods for the annual interviews are available for
download.
• The structured face-to-face interviews include items on a range of topics; this bulletin is
focused on recent (past six month) consumption of ‘capsules contents unknown’ (i.e.,
where no information is communicated regarding likely contents).
The aims of this bulletin are to explore:
1. National and jurisdictional trends in use of 'capsules contents unknown' among a
sentinel sample of people who regularly use ecstasy and other illicit stimulants.
2. Trends in quantity and frequency of use, as well routes of administration, amongst this
group.
Figure 1 shows that the percentage of participants reporting recent and lifetime use
followed a similar trend, with the highest rate of consumption in 2017 at 20% and 35%
respectively. Recent use of capsules contents unknown increased from 7%-10% in 2013-
2015 to 20% in 2017, with 18% reporting recent use in 2018. Lifetime use increased to
35% in 2017 from 18-21% in 2013-2015 (34% in 2018).
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Figure 2 demonstrates the trend over time in the recent use of capsules with unknown
contents across each of the jurisdictions. The percentage reporting recent use in all
jurisdictions except Queensland have increased from 2013, when the questionnaire
item was first introduced to EDRS. Tasmania in particular has demonstrated a sharp
increase in the rate of consumption, from 11% in 2014 to 36% in 2018. In 2018, recent
use was highest in Tasmania (36%) and lowest in New South Wales (12%) and
Queensland (12%).
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Frequency
Median days of 
consumption
2
(IQR 1-4)
2
(IQR 1-2)
2 
(IQR 1-2)
1
(IQR 1-2)
2
(IQR 1-3)
2
(IQR 1-2)
% Weekly or more 
frequent consumers
1% 3% 0% 1% 1% 1%
Quantity (per session)
Median capsules in a 
typical session
N/A N/A N/A
1
(IQR 1-2)
1
(IQR 1-2)
1 
(IQR 1-2)
% ≥2  capsules in an 
average session
N/A N/A N/A 28% 22% 38%
Median capsules in 
maximum session
N/A N/A N/A
1 
(IQR 1-2)
1
(IQR 1-2)
1
(IQR 1-2)
% ≥2  capsules in a 
maximum session
N/A N/A N/A 36% 30% 50%
Route of administration
% Swallowed 89% 94% 87% 92% 92% 97%
% Snorted 11% 14% 15% 14% 14% 12%
% Inject 0% 0% 0% 0% 0% 0%
% Smoke 0% 0% 0% 0% 1% 0%
% Shelve N/A N/A N/A 0% 1% 1%
Table 1 shows that, across the years, participants have typically reported using capsules
with contents unknown for a median of 2 days in the past six months. Very few participants
report weekly or more frequent use of capsules with contents unknown.
While the median number of capsules with unknown contents consumed at a given time
has remained consistent, there has been an increasing number of participants reporting use
of more than one capsule at a time. This number increased from 28% in 2016 to 38% in
2018, with earlier years not reporting on this item.
There is consistency in the primary route of administration amongst consumers across the
years, with approximately nine in ten reporting swallowing and just over one in ten each
year report snorting.
The percentage of the EDRS sample reporting recent use of ‘capsules contents unknown’
increased from 2013 to 2018. This trend coincides with an increase in the use of ecstasy
capsules (50% in 2013 to 72% in 2018) among the EDRS sample, simultaneous to a
decline in the consumption of ecstasy pills (100% in 2003; 78% in 2017; 75% in 2018). The
current findings could indicate a preference in the form of substance (i.e., for capsules),
noting that EDRS participants report perceived greater purity of ecstasy crystal and
capsules over pills .
Within the population of participants who reported use of capsules contents unknown, 85%
also reported using ecstasy capsules. However, the median number of capsules consumed
in a typical session was less for capsules contents unknown (median one capsule in a
typical session of use) than ecstasy capsules (median two capsules) [4]. In addition, the
median number of days of ecstasy capsule consumption in the past six months was six
days, while median frequency of capsules with unknown contents was two days [4]. This
indicates that in the absence of information regarding the likely contents of a substance,
people who use these drugs may take precautionary measures to reduce risk (i.e., lower
quantity and frequency of use).
The increase in the use of capsules with unknown contents is of particular concern as the
illicit drug market is unregulated and is continually evolving with new psychoactive
substances which often have greater potency than traditional drugs [5-6]. In the absence of
substance checking services, it is pivotal for consumers to engage in information exchange
regarding their (likely) substance to implement harm reduction methods such as a decrease
in frequency or quantity of consumption [7]. Research into the demographics of people who
use capsules with unknown contents (or other substances in the absence of
communication of likely contents) could be conducted to identify target populations for
messaging around harm reduction, as well as broader practices and harms from
consuming substances in the absence of communication regarding likely content.
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